Aventis Lantus Phase IIIb Trial To Compare Nocturnal Hypoglycemia Rates
Executive Summary
Aventis is conducting a Phase IIIb trial to compare the incidence of nocturnal hypoglycemia with its insulin glargine product Lantus and NPH human insulin (Lilly's Humulin or Novo Nordisk's Novolin) in patients with type 2 diabetes.
You may also be interested in...
Aventis Insuman Fourth Quarter NDA Planned After Manufacturing Changes
Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials